Login to Your Account

J&J, Bavarian Nordic double up on HPV vaccine in $171M deal

By Cormac Sheridan
Staff Writer

Friday, December 18, 2015

DUBLIN – Bavarian Nordic A/S is banking $9 million up front and could get up to $162 million more in milestone payments from a new partnership with Johnson & Johnson's Janssen Pharmaceuticals arm to develop a therapeutic vaccine for HPV infection.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription